Using artificial intelligence to improve treatment decisions for skin cancer
Official title: Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence
Funded at Dana-Farber Cancer Inst · NIH-10988558 · Data updated 2026-11-12
This study is looking at a common skin cancer called cutaneous squamous cell carcinoma (cSCC) to help doctors better predict how patients will do and choose the best treatments for them, using smart computer technology to analyze tumor information and improve care for everyone.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $693,156 |
| NIH project number | 1R21EB035247-01A1 |
| Project ID | NIH-10988558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cutaneous squamous cell carcinoma who may benefit from personalized treatment strategies.
✕Less likely to help
Patients with other types of skin cancer or those whose cSCC is already at an advanced stage may not benefit from this research.
What this research studies
This research focuses on cutaneous squamous cell carcinoma (cSCC), a common type of skin cancer, and aims to enhance how doctors predict patient outcomes and select therapies. By developing advanced artificial intelligence algorithms, the project will analyze a large dataset of cSCC tumors, including their histopathology and clinical outcomes. The AI models will help identify patients at higher risk for severe disease, allowing for more tailored and effective treatment plans while minimizing unnecessary side effects for those at lower risk.
Why it matters
Potential benefit: If successful, this research could lead to more accurate treatment decisions for patients with cutaneous squamous cell carcinoma, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in using artificial intelligence for cancer prognosis and treatment selection, indicating that this approach could be effective.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Lotter, William Edward — Dana-Farber Cancer Inst
- Study coordinator: Lotter, William Edward
Related research
Other NIH-funded projects on the same topics.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
AI-powered digital pathology to tailor cancer treatment decisions
A team at Emory is building an AI-powered platform that analyzes cancer slides to help doctors choose the right therapies and avoid unnecessary chemotherapy or radiation for patients.
-
Harnessing the body's response to leptospirosis to aid diagnosis and prognosis
This grant aims to develop new ways to detect leptospirosis earlier and predict how severe it might become by studying the body's own response.
-
Harnessing the body’s response to Leptospirosis to improve diagnosis and prognosis
A research program at UCLA aims to use how the body responds to leptospirosis to make better diagnoses and predict outcomes for patients.
-
Harnessing the body's response to a dangerous infection to help diagnose and predict outcomes
A large, multi-project effort aims to use how the body reacts to leptospirosis to improve diagnosis and prognosis for patients affected by this infection.
-
Harnessing the body’s response to leptospirosis for diagnosis and prognosis
A multi-site team is working to develop how the body naturally responds to leptospirosis to improve how we diagnose the infection and predict its course.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.